Sliding Sleeve Attachment for an Injection Device

Patent metadata

Field	Value
Publication number	US-2016129198-A1
Application number	US-201414897388-A
Country	US
Kind code	A1
Filing date	Jun 11, 2014
Priority date	Jun 11, 2013
Publication date	May 12, 2016
Grant date	—

Abstract

There is provided an injection device 110 comprising a housing 112 adapted to receive a syringe having a discharge nozzle, the syringe being moveable in the housing on actuation of the injection device along a longitudinal axis from a retracted position in which the discharge nozzle is contained within the housing and an extended position in which the discharge nozzle of the syringe extends from the housing through an exit aperture 118 at a distal end of the device, a sliding component 126 which extends, when in a first position, from the aperture, and is movable towards the housing into a second, retracted, position, wherein the sliding component comprises, at its distal end, a removable contact element 220.

First claim

1 . An injection device comprising:
a housing adapted to receive a syringe having a discharge nozzle, the syringe being moveable in the housing on actuation of the injection device along a longitudinal axis from a retracted position in which the discharge nozzle is contained within the housing and an extended position in which the discharge nozzle of the syringe extends from the housing through an exit aperture at a distal end of the device; a sliding component which extends, when in a first position, from the aperture, and is movable towards the housing into a second, retracted, position, wherein the sliding component comprises, at its distal end, a removable contact element.

2 . The injection device according to claim 1 , further comprising:
an actuator; and a drive adapted to be acted upon by the actuator and in turn act upon the syringe to advance it from its retracted position to its extended position and discharge its contents through the discharge nozzle.

3 . The injection device according to claim 1 or claim 2 , wherein the sliding component is part of a locking mechanism moveable from an engaged position, when the sliding component is in its first position, to a disengaged position, when the sliding component is in its second position, and adapted to prevent actuation of the device when it is in its engaged position and permit actuation of the device when it is in its disengaged position.

4 . The injection device according to any preceding claim, wherein the contact element is adapted for contact with the skin surface.

5 . The injection device according to any preceding claim, wherein the contact element is configured to draw the user's skin towards the exit aperture.

6 . The injection device according to claim 5 , wherein the contact element comprises a resilient portion for adhering the contact element with the skin such that the end of sliding component is fixedly located on the skin.

7 . The injection device according to claim 6 , wherein the contact element comprises two resiliently biased arms.

8 . The injection device according to any one of claims 1 to 5 , wherein the contact element comprises a flexible cap for adhering the contact element with the skin such that the end of sliding component is fixedly located on the skin.

9 . The injection device according to any one of claims 1 to 4 , wherein the contact element comprises adhesive for adhering the contact element with the skin, such that the end of the sliding component is fixedly located on the skin.

10 . The injection device according to any one of claims 1 to 4 , wherein the contact element has an inner and an outer diameter and a surface extending between the inner and the outer diameter and wherein the outer diameter is larger than the diameter of the sliding component.

11 . The injection device according to claim 10 , wherein the inner diameter is dimensioned for locating on the sliding component.

12 . The injection device according to any one of claims 1 to 4 , wherein the contact element comprises at least one contact member having a surface for engaging a surface of the skin.

13 . The injection device of claim 12 , wherein the contact member extends radially from the longitudinal axis of the housing.

14 . The injection device of any one of claim 12 or 13 , wherein the contact element comprises a plurality of contact members.

15 . The injection device according to any one of claims 12 to 14 , wherein the contact element comprises three contact members, spaced equidistantly from each other.

16 . The injection device of any of 12 to 15 wherein the contact member comprises a second surface for engaging a surface of the housing.

17 . The injection device of any preceding claim, wherein the sliding component comprises a sliding sleeve.

18 . The injection device of claim 17 , wherein the contact element is disposed on the distal end of the sliding sleeve.

19 . The injection device of any preceding claim, wherein the contact element is disposable.

20 . A kit comprising:
an injection device comprising:
a housing adapted to receive a syringe having a discharge nozzle, the syringe being moveable in the housing on actuation of the injection device along a longitudinal axis from a retracted position in which the discharge nozzle is contained within the housing and an extended position in which the discharge nozzle of the syringe extends from the housing through an exit aperture at a distal end of the device;
a sliding component which extends, when in a first position, from the aperture, and is movable towards the housing into a second, retracted, position; and

a contact element adapted to be removably attached to the distal end of the sliding component.

21 . A device substantially as hereinbefore described with reference to the accompanying drawings.

22 . An injection device according to any of the preceding claims containing a substance selected from the group consisting of:
golimumab, hormones, antitoxins, substances for the control of pain, substances for the control of thrombosis, substances for the control or elimination of infection, peptides, proteins, human insulin or a human insulin analogue or derivative, polysaccharide, DNA, RNA, enzymes, antibodies, oligonucleotide, antiallergics, antihistamines, anti-inflammatories, corticosteroids, disease modifying anti-rheumatic drugs, erythropoietin, or vaccines, for use in the treatment or prevention of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency, toxicity, pain, thrombosis, infection, diabetes mellitus, diabetic retinopathy, acute coronary syndrome, angina, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anaemia, or myelodysplasia, or in the expression of protective immunity.

23 . A substance selected from the group consisting of: golimumab, hormones, antitoxins, substances for the control of pain, substances for the control of thrombosis, substances for the control or elimination of infection, peptides, proteins, human insulin or a human insulin analogue or derivative, polysaccharide, DNA, RNA, enzymes, antibodies, oligonucleotide, antiallergics, antihistamines, anti-inflammatories, corticosteroids, disease modifying anti-rheumatic drugs, erythropoietin, or vaccines,
for use in the treatment or prevention of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency, toxicity, pain, thrombosis, infection, diabetes mellitus, diabetic retinopathy, acute coronary syndrome, angina, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anaemia, or myelodysplasia, or in the expression of protective immunity, by delivery of said substance to a human subject using an injection device according to any one of claims 1 to 21 .

24 . An injection device for use in the treatment or prevention rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency, toxicity, pain, thrombosis, infection, diabetes mellitus, diabetic retinopathy, acute coronary syndrome, angina, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anaemia, or myelodysplasia, or in the expression of protective immunity,
by delivery of a substance selected from the group consisting of: golimumab, hormone

Assignees

• Cilag Gmbh Int

Inventors

• Bitar Ahmad
• Jennings Douglas Ivan

Classifications

• A61M5/2033 Primary

  Spring-loaded one-shot injectors with or without automatic needle insertion (multishot dosing syringes A61M5/31525, needle insertion only A61M5/3287) · CPC title

• A61M2005/2006

  Having specific accessories · CPC title

• A61M5/425

  Protruding skin to facilitate piercing, e.g. vacuum cylinders, vein immobilising means · CPC title

• A61M5/32

  Needles; Details of needles pertaining to their connection with syringe or hub (infusion needles A61M5/158); Accessories for bringing the needle into, or holding the needle on, the body {(A61M5/42, A61M5/46 take precedence; guide needles for catheters A61M25/065)}; Devices for protection of needles {(apparatus specially adapted for cleaning or sterilising needles A61M5/001)} · CPC title

• A61M2005/206

  With automatic needle insertion · CPC title